A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty

BACKGROUND: Oliceridine (TRV130), a novel μ-receptor G-protein pathway selective (μ-GPS) modulator, was designed to improve the therapeutic window of conventional opioids by activating G-protein signaling while causing low β-arrestin recruitment to the μ receptor. This randomized, double-blind, pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Singla, Neil, Minkowitz, Harold S, Soergel, David G, Burt, David A, Subach, Ruth Ann, Salamea, Monica Y, Fossler, Michael J, Skobieranda, Franck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638571/
https://www.ncbi.nlm.nih.gov/pubmed/29062240
http://dx.doi.org/10.2147/JPR.S137952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638571/
https://www.ncbi.nlm.nih.gov/pubmed/29062240
http://dx.doi.org/10.2147/JPR.S137952

Ejemplares similares